|
⚲
|
| Keyboard |
| Perceptive Advisors LLC
✚
|
|
|---|---|
| CRD # | 154703 |
| SEC # | 801-71841 |
| CIK # | 0001224962 |
| AUM | 11.77 B (2026-03-30) |
| Employees | 49 (57% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 646-205-5300 |
| Address | 51 Astor Place New York, NY 10003 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| In the News | |
|---|---|
| Thu, 30 Jul 2026 | Perceptive Advisors LLC Initiates a Major Stake in Perceptive Ca — GuruFocus |
| Fri, 10 Jul 2026 | LeonaBio (LONA) awards 28,000 stock options tied to Perceptive Advisors board role — Stock Titan |
| Tue, 07 Apr 2026 | Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors — Yahoo Finance |
| Fees and Compensation — Form ADV Part 2A (7/13/2026) [Brochure] |
|---|
ITEM 5: FEES AND COMPENSATION The Advisor receives compensation for its advisory services, including management fees and performance- based compensation, as set forth in the applicable governing documents of the funds and other investment vehicles it advises. Fee structures vary depending on the applicable fund, vehicle, investor class and strategy. The Perceptive Life Sciences Funds The Advisor receives a management fee (the “Management Fee”), payable at the feeder fund level, calculated based on the net asset value of the Perceptive Life Sciences Funds. The Management Fee is payable monthly at the beginning of each month. Management Fee calculation methodology is described in detail in each feeder fund’s Governing Documents. The Advisor, in its discretion, may waive all or any portion of the Management Fee for any investor and may agree that a portion of its Management Fee be paid to third parties. Each feeder fund also reimburses and/or advances to the Advisor a maximum of 1% per annum of the average month-end net asset value of each feeder fund for certain of the Advisor’s administrative and management costs and expenses, including without limitation computer equipment and services, office space and utilities, salaries and bonuses, and other overhead expenses of the Advisor, except to the extent such costs and expenses are provided through “soft dollars” as described in Item 12 herein. Certain investors in the feeder funds hold shares or limited partnership interests that are not subject to this 1% fee. Please see Item 6 for a discussion of the Advisor’s performance-based compensation. The Credit Opportunities Funds The Advisor receives a Management Fee, calculated and payable quarterly in advance. Management Fee calculation methodology is described in detail in each Credit Opportunities Fund’s Governing Documents. Please see Item 6 for a discussion of the Advisor’s performance-based compensation. The Venture Funds The Advisor receives a Management Fee, calculated and payable quarterly in advance. Management Fee calculation methodology is described in detail in each Venture Fund’s Governing Documents. Please see Item 6 for a discussion of the Advisor’s performance-based compensation. The Capital Solutions Funds The Advisor receives a Management Fee, calculated and payable quarterly in advance. Management Fee calculation methodology is described in detail in the Capital Solutions Fund’s Governing Documents. The Adviser, in its discretion, may waive a portion of the Management Fee in exchange for a reduction in the Adviser’s cash capital contribution obligation and/or corresponding interest in the Capital Solutions Funds’ profits. Please see Item 6 for a discussion of the Advisor’s performance-based compensation. The Advisor, in its discretion, may waive all or any portion of the Management Fee for any investor. Generally 100% of the Life Sciences Funds’ the Credit Opportunity Funds’, the Venture Funds’ and Capital Solutions Fund’s pro rata share of any amount of director’s fees, consulting fees, commitment fees, break- up fees, monitoring fees, success fees or other remuneration paid to the general partner of the applicable fund, the Advisor or any of the Advisor’s principals by or on behalf of portfolio companies, net of expenses, will be treated as an offset against future Management Fees or will reduce Fund expenses; provided, however, that the Management Fee will not be reduced below zero for the applicable fund. Generally, either the Advisor bears the costs of any placement fees for its Funds, or any such fees offset the Management Fee of the applicable fund. Separate Account The Separate Account is not charged any fees by the Advisor. Co-investment Vehicles The Advisor establishes specific fee schedules with respect to each co-investment vehicle. Fees on co- investment vehicles may be greater than, equal to, or lower than, the fees applicable to the Client Accounts alongside which co-investment vehicles participate in investment opportunities, and may include reduced or no management fees, different carried interest or incentive allocations, and/or different expense arrangements. The Advisor, in its sole discretion, may waive or lower the fees for some or all of the investors in the co-investment vehicle. Such waiver or reduction of the fees will not result in any increase in the fee or expense burden on other investors in the co-investment vehicles. Expenses Except as otherwise agreed with any particular Client Account in the relevant Governing Documents, generally each Client Account is responsible for, among other things, all third-party costs and expenses related to their investments and operations, including all expenses and costs incurred in investigating, developing, negotiating, structuring, acquiring, trading, settling, monitoring and holding portfolio investments and prospective portfolio investments (whether or not consummated); travel, legal, tax and accounting expenses in connection therewith; broken deal expenses; costs and expenses related to a potential investment idea, including expenses related thereto which may consist of reimbursement to the Advisor for a portion of the compensation paid to an employee or consultant of the Advisor including an entrepreneur-in-residence and an applicable portion of the overhead of the Advisor; expenses related to the registration, qualification or exemption of any Fund under any applicable laws; brokerage fees and commissions and prime brokerage fees, clearing and settlement charges, bank services fees, custodial expenses, agent bank and other bank service fees and other investment costs; payments to legal counsel, tax advisors, auditors, accountants, administrators, directors, appraisers, custodians, consultants and other outside advisors; expenses of the advisory boards attributable to any of the Funds; insurance; market data ... |
| Account Minimums and Types of Clients — Form ADV Part 2A (7/13/2026) [Brochure] |
|---|
ITEM 7: TYPES OF CLIENTS The Advisor’s clients are the Funds, the Separate Account, and co-investment vehicles. Each Fund’s Governing Documents specify the eligibility criteria and minimum investment requirements. Although the Advisor has the authority to accept subscriptions of a lesser amount, the required minimum initial investment in the Funds can range from $500,000 to $5,000,000 depending on the Fund. Investors in the Client Accounts and co-investment vehicles consist primarily of institutional investors, financial institutions, other investment funds, pension plans, endowments, foundations, family offices, and high-net-worth individuals. The Advisor requires Fund investors and co-investors to make representations concerning their financial sophistication, eligibility to invest, and ability to bear the risk of loss of their entire investment. The Advisor may, in its discretion, accept investors on terms that differ from those offered to other investors, including through side letters or other arrangements, as permitted by the relevant Governing Documents. |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Praxis Precision Medicines Inc | 0.7 | ||
| Celcuity Inc | 0.4 | ||
| Ascendis Pharma A/S | 0.4 | ||
| Roivant Sciences Ltd | 0.2 | ||
| Rhythm Pharmaceuticals Inc | 0.2 | ||
| Aeglea Biotherapeutics Inc | 0.2 | ||
| Nuvalent Inc | 0.2 | ||
| Edgewise Therapeutics Inc | 0.1 | ||
| Protagonist Therapeutics Inc | 0.1 | ||
| Apogee Therapeutics Inc | 0.1 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Perceptive Credit Opportunities Fund V LP | [2026-02-23] | 677.8 M | |
| Filed 2025-10-29 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | Perceptive SP G LP | 2025-03-26 | 7.2 M | |
| Other | PCOF Phoenix II AIV III LP | 2024-03-28 | 1.2 M | |
| PE | Perceptive Capital Solutions Fund A LP | [2024-03-28] | 5.6 M | 62.1 M |
| Filed 2025-02-04 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Not Applicable | ||||
| PE | Perceptive Capital Solutions Fund LP | [2024-03-28] | 218.8 M | 364.4 M |
| Filed 2025-02-04 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Not Applicable | ||||
| PE | PX Venture C LLC | [2024-03-20] | 5.1 M | |
| Filed 2023-07-18 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| Other | PCOF EQ AIV IV LP | 2022-03-31 | 3.3 M | |
| HF | Perceptive Credit Opportunities Fund IV LP | [2022-03-31] | 1,495.1 M | |
| Filed 2022-07-21 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Not Applicable | ||||
| PE | Perceptive SP C LP | 2022-03-31 | 3.9 M | |
| PE | Perceptive SP D LP | 2022-03-31 | 2.7 M | |
| View All | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 25 | 11.7 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 1 | 0.1 |
| Total | 26 | 11.8 |
| By Discretionary | ||
| Discretionary | 26 | 11.8 |
| Non-Discretionary | 0 | 0.0 |
| Total | 26 | 11.8 |
| By Non-United States Persons | ||
| Non-United States Persons | 4.6 | |
| United States Persons | 7.1 | |
| Total | 26 | 11.8 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Scott Dakers | Director | 141 | 35 | |
| Ernest Morrison | Director | 27 | 11 | |
| Joseph Edelman | Director, Executive Officer | 35 | 2 | |
| Perceptive Credit Opportunities GP LLC | Director, Executive Officer | 19 | 2 | |
| Perceptive Xontogeny Venture GP LLC | Executive Officer | 4 | 2 | |
| Perceptive Discovery GP LLC | Executive Officer | 3 | 2 | |
| Lev LB Holdings GP LLC | Executive Officer | 1 | 1 | |
| Perceptive LS GP LLC | Executive Officer | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001224962] | |
| 3 | [0001224962] | |
| 4 | [0001224962] | |
| SC 13D | [0001224962] | |
| SC 13G | [0001224962] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $1.9B |
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| LEI | 54930051M1DQYADROP30 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Solid Biosciences Inc SLDB
Pre-Funded Warrant (right to buy) · derivative
|
2026-03-09 | Grant | 8,912,655 | $5.61 | 49,999,995 |
|
MeiraGTx Holdings PLC MGTX
Ordinary Shares
|
2025-12-31 | Disposed to issuer | 2,300,000 | $7.91 | 18,193,000 |
|
LeonaBio Inc ATHA
Series A Warrant (right to buy) · derivative
|
2025-12-23 | Grant | 1,279,526 | $6.35 | 8,124,990 |
|
LeonaBio Inc ATHA
Pre-Funded Warrant (right to buy) · derivative
|
2025-12-23 | Grant | 1,372,935 | $6.35 | 8,718,137 |
|
LeonaBio Inc ATHA
Series B Warrant (right to buy) · derivative
|
2025-12-23 | Grant | 3,543,307 | $6.35 | 22,499,999 |
|
LeonaBio Inc ATHA
Common Stock
|
2025-12-23 | Grant | 329,756 | $6.35 | 2,093,951 |
|
LeonaBio Inc ATHA
Pre-Funded Warrant (right to buy) · derivative
|
2025-12-23 | Grant | 457,645 | $6.35 | 2,906,046 |
|
LeonaBio Inc ATHA
Series B Warrant (right to buy) · derivative
|
2025-12-23 | Grant | 1,181,101 | $6.35 | 7,499,991 |
|
LeonaBio Inc ATHA
Common Stock
|
2025-12-23 | Grant | 989,270 | $6.35 | 6,281,864 |
|
LeonaBio Inc ATHA
Pre-Funded Warrant (right to buy) · derivative
|
2025-12-23 | Grant | 5,502,402 | ||
|
LeonaBio Inc ATHA
Series A Warrant (right to buy) · derivative
|
2025-12-23 | Grant | 3,838,583 | $6.35 | 24,375,002 |
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2025-11-13 | Sell | 3,213 | $3.90 | 12,531 |
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2025-11-13 | Sell | 28,597 | $3.90 | 111,528 |
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2025-11-12 | Sell | 7,862 | $4.06 | 31,920 |
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2025-11-12 | Sell | 883 | $4.06 | 3,585 |
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2025-11-11 | Sell | 537 | $4.31 | 2,314 |
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2025-11-11 | Sell | 4,783 | $4.31 | 20,615 |
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2025-11-10 | Sell | 16,633 | $4.54 | 75,514 |
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2025-11-10 | Sell | 1,869 | $4.54 | 8,485 |
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2025-11-07 | Sell | 17,746 | $4.75 | 84,294 |
| showing 20 of 200 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
BSP CLO Management LLC
✚
|
NY | 12.24 B |
|
Pacific Private Fund Advisors LLC
✚
|
CA | 12.24 B |
|
Canyon Capital Advisors LLC
✚
|
TX | 11.92 B |
|
Levine Leichtman Capital Partners LLC
✚
|
CA | 11.88 B |
|
Paradigm Operations LP
✚
|
CA | 11.87 B |
|
Entrust Global Partners LLC
✚
|
NY | 11.82 B |
|
TPG Solutions Advisors LLC
✚
|
TX | 11.61 B |
|
One William Street Capital Management LP
✚
|
NY | 11.30 B |
|
Guggenheim Corporate Funding LLC
✚
|
NY | 11.29 B |
|
Orchard Global Asset Management LLP
✚
|
11.28 B |